multiples ont été décrites chez l’enfant dont certaines étaient associées à une neurofibromatose de type 1 ou à un syndrome polymalformatif [6]. Une évolution maligne, de pronostic sombre, rapidement péjoratif peut s’observer dans 1 à 3 % des cas, surtout décrite dans les localisations viscérales profondes ou aux tissus mous, et qui impose la recherche de localisations secondaires (poumon, foie, os) [1,7]. Cette évolution maligne doit être suspectée cliniquement devant une taille tumurale de plus de 4 cm, une croissance rapide, l’existence de plages nécrotiques et hémorragiques, et confirmée sur les critères histologiques de malignité décrit par Famburg du fait de la difficulté du diagnostic histologique de malignité, parfois posé seulement devant l’existence de métastases.


Les diagnostics différentiels cliniques sont, au niveau cutané, ceux de tout nodule tumoral et plus particulièrement le neurofibrome, le rhabdomyome et le carcinome épidermoïde. Le traitement repose sur une exérèse chirurgicale complète visant des marges saines afin d’éviter les récidives [8]. La technique chirurgicale de Mohs permet de réduire les marges d’exérèse, en particulier dans certaines localisations telles que les organes génitaux externes et les extrémités. La radiothérapie et la chimiothérapie n’ont pas d’indication en raison de la résistance de cette tumeur à ces thérapeutiques et de leurs effets carcinogènes potentiels. Une surveillance régulière et sur le long terme est recommandée afin de détecter d’éventuelles récidives ou une transformation maligne.

Déclaration d’intérêts : les auteurs déclarent ne pas avoir de conflits d’intérêts en relation avec cet article.

Références


Houyam Moundib1, Fouzia Hali1, Kawtar Zouhair1, Hakima Benchikh1, Hicham Jerrah2, El Hassam Boukni3, Farida Mamissi1

1CHU Ibn Rochd, service de dermatologie vénéréologie, 20100 Casablanca, Maroc
2CHU Ibn Rochd, service de chirurgie plastique et réparatrice, 20100 Casablanca, Maroc
3CHU Ibn Rochd, service d’anatomie pathologique, 20100 Casablanca, Maroc

Correspondance : Houyam Moundib, service de dermatologie vénéréologie, rue des Hôpitaux, 20100 Casablanca, Maroc. houyammoundib@hotmail.com

Reçu le 16 mars 2014
Accepté le 15 mai 2014
Disponible sur internet le 11 septembre 2014

http://dx.doi.org/10.1016/j.jpm.2014.05.011 © 2014 Elsevier Masson SAS Tous droits réservés.

Octreotide for Heyde’s syndrome: A case report

Syndrome de Heyde et octreotide : à propos d’un cas

In 1958, E.C. Heyde reported a case series of 10 patients with calcific aortic valve stenosis and massive gastrointestinal bleeding [1]. Submucosal angiodyplasia were subsequently identified as the source of bleeding, however the mechanisms of such an association are elusive and the best treatment strategy remains controversial.

Case report

A 72-year-old man presented with relapsing enterorrhagia and progressive anemia. Multiple sites of complex mucosal angiodysplasia in the jejenum were shown upon video capsule panendoscopy after repeated upper and lower gastrointestinal tract endoscopies and angiographic studies that failed to disclose the origin of the bleeding. His previous history included a severe calcified aortic stenosis (mean pressure gradient of 56 mmHg, maximal gradient of 77 mmHg, functional area of 0.87 cm²), hypertension, coronary artery disease, chronic kidney disease stage III, and a re-stenosis of a left internal carotid artery graft, for which the patient was taking clopidogrel, simvastatin, ramipril, and metoprolol. Laboratory findings disclosed iron deficiency and anemia with hemoglobin (Hb) 6.1 g/dL; two units of packed red blood cells were transfused, clopidogrel was withdrawn, and selective angiography of the superior mesenteric artery with embolization of multiple areas of the jejunal angiodysplasia was performed. The patient was discharged on the 6th day with Hb 10.5 g/dL and no evidence of active bleeding from the gastrointestinal tract. He remained stable and clopidogrel...
(75 mg daily) and erythropoietin (10,000 IU weekly) were added, however two weeks later he presented again with melena and anemia (Hb 7.2 g/dl) for which three units of packed red blood cells were transfused. The patient refused to undergo valve replacement because of the high surgical risk and was discharged on the 8th day with advice to not resume clopidogrel or other anti-platelet medications. At this time, we started octreotide (20 mg monthly). Over the further follow-up, the patient had no relapse of gastrointestinal bleeding and is currently doing well after more than two years with stable Hb at around 11 g/dl. During this time, he was not taking any anti-platelet or anticoagulant medications and laboratory studies repeatedly showed normal values of bleeding time (3 minutes, normal 2–7), platelet count (276/mm³, normal 150–300/mm³), activated partial-thromboplastin time (29 seconds, normal 27–35), international normalized ratio (1.1, normal 0.9–1.1), factor VIII coagulant level (93 IU/dl, normal 50–150), von Willebrand factor (vWF) antigen (110 IU/dl, normal 50–150) and vWF ristocetin cofactor activity (125 IU/dl, normal 50–150).

Discussion
Heyde’s syndrome refers to an acquired type 2A von Willebrand syndrome that is characterized by the loss of the largest polymers of vWF [2]. The high shear forces generated through the stenotic aortic valve are postulated to expose the bond between amino acids 842 and 843 of vWF, which is sensitive to the action of ADAMTS13, ultimately resulting into the proteolysis and loss of the highest-molecular-weight vWF polymers [2]. Abnormalities in vWF function can be found in up to 92% of patients with severe aortic stenosis and seem to correlate significantly with the hemodynamic severity of valve stenosis [3]. The full resolution of vWF abnormalities and ceasing of gastrointestinal bleeding within hours of valve replacement and their reappearance in close relationship with the recurrence of the valve stenosis or when there is a mismatch between the patient and the prosthesis lend support to the central role of this mechanism [3]. Furthermore, vWF proteolysis and loss of the highest-molecular-weight vWF polymers have been demonstrated also in other cardiac disorders characterized by high shear stress such as hypertrophic obstructive cardiomyopathy and the use of left ventricular assist device support [2]. It remains unclear if vWF is directly involved in angiogenesis under physiological conditions; nonetheless qualitative or quantitative vWF defects are associated with the development of gastrointestinal angiodysplasia and greatly increase both the bleeding propensity and its severity [2].

Our patient had all the clinical features of Heyde’s syndrome. Even though we did not perform gel electrophoresis of vWF, i.e. the gold standard to show the loss of large vWF polymers, nonetheless all other laboratory studies did not disclose any abnormalities of platelets, coagulation parameters and vWF levels and function. It should be taken into account that all these tests remained within the normal range over a prolonged follow-up after the start of octreotide therapy and while the patient was not taking any anti-platelet or anticoagulant medications. Even though these findings reasonably rule out the diagnosis of type2A von Willebrand syndrome, it should be noted that all patients with aortic stenosis and acquired von Willebrand syndrome in the series from Vincentelli et al. had normal levels of factor VIII coagulant activity and vWF antigen [3]. We speculate our case could represent the tip of the iceberg of a subset of patients with Heyde’s syndrome in whom the underlying mechanistic explanation for the association between aortic stenosis, intestinal angiodysplasia, and gastrointestinal bleeding might not be provided by the development of type 2A von Willebrand syndrome. Alternative mechanisms ranging from age-related degeneration to mucosal ischemia and cholesterol embolization have been advocated to explain the development of angiodysplasia and gastrointestinal bleeding in patients with aortic stenosis [4]. Differences in genetic backgrounds and causative mechanisms that are so far unrecognized could lead to the definition of Heyde’s subsyndromes, which will probably need different therapeutic approaches. There is no consensus about the best treatment strategy of gastrointestinal bleeding in patients with Heyde’s syndrome. A wide spectrum of options are available and current evidence indicates that octreotide and other somatostatin analogues can be helpful particularly in patients with refractory gastrointestinal bleeding associated with Willebrand disease and other coagulation disorders and in those at high risk for invasive procedures [5]. A wide spectrum of mechanisms ranging from decreased splanchnic blood flow to increased vascular resistance and improved platelet aggregation could be involved in the action of octreotide in this setting [5]. Furthermore, anecdotal experience in patients with von Willebrand’s disease and bleeding intestinal angiodysplasia suggests that the response to octreotide may be mediated by increased levels and functional activity of vWF [2]. However, few studies have focused on the use of somatostatin analogues in patients with Heyde’s syndrome. There is only one report of the successful treatment with octreotide of one patient with Heyde’s syndrome who had no improvement in gastrointestinal bleeding after aortic valve replacement [6]. Furthermore, Rennysen et al. have described a patient in whom left ventricular assist device-related gastrointestinal hemorrhage was effectively stopped with a combination of subcutaneous and intramuscular depot formulations of octreotide [7]. In our case, the patient remained free of bleeding while on long-term treatment with octreotide with stable Hb levels over more than two years of follow-up. This suggests that the duration of octreotide therapy could be the critical point to achieve the full control of gastrointestinal bleeding in Heyde’s syndrome.

In conclusion, we suggest that octreotide and possibly other somatostatin analogues could be a valuable alternative to
aortic valve replacement for the management of gastrointestinal bleeding in patients with Heyde’s syndrome who are not eligible for aortic valve replacement.

**Disclosure of interest:** the authors declare that they have no conflicts of interest concerning this article.

**References**


Giuseppe Fumaraoro, Laura Gasbarrone, Giovanni Minisola
San Camillo hospital, department of internal medicine, 00152 Rome, Italy

**Correspondence:** Giuseppe Fumaraoro
San Camillo hospital, department of internal medicine, Circonvallazione Gianicolense, 00152 Rome, Italy.
gfumaraoro@scamilloforlanini.rm.it

Received 19 February 2014
Accepted 10 April 2014
Available online 5 September 2014

http://dx.doi.org/10.1016/j.ijpm.2014.04.020
© 2014 Elsevier Masson SAS Tous droits réservés.

**A pregnancy-related spontaneous coronary artery dissection: Psychiatric considerations**

Dissection spontanée d’une artère coronaire en post-partum : considérations psychiatriques

Peripartum spontaneous coronary artery dissection (SCAD) is a rare event [1,2]. Most cases are discussed from a cardiologic standpoint. We present a case where the psychic impact of such illness is highlighted to stress the need for closer psychiatric monitoring in these instances. Psychological stressors might contribute to etiology either directly or indirectly through the use of hormones to foster pregnancy. We will stress here the psychic consequences.

**Case report**

A 39-year-old woman, six months after delivering her second child, was admitted to hospital for acute chest pain and loss of consciousness. A coronography showed an acute dissection of the left anterior descending artery (LAD). The ECG was suggestive of an antero-lateral infarct and Troponin T elevated up to 5861 ng/L (N ≤ 50 ng/L). An echocardiography showed a slight pericardic effusion and a left ventricle ejection fraction around 25%. Her past medical history included hypothyroidism and obesity (BMI: 37 kg/m²), but pertinent negatives for standard cardiovascular risks were substance abuse, blood dyscrasias, dyslipidemia, smoking, hypertension, cardiac family history. She reported having taken progesterone (prometrium) for fertility (100 mg for 3 months; 200 mg for 2 months) and she had resumed oral contraceptives intake two months after delivery. The medical treatment was conservative, mainly antiplatelet therapy.

Four days after admission, a psychiatric consultation was requested to address her anxiety and distress. The patient was a college teacher in a stable marital relationship. She had a four-year-old daughter and a six-month-old baby girl. She has had two previous spontaneous abortions prior to her deliveries. She reported a difficult latest pregnancy because of important symptoms of hyperemesis gravidarum. She consulted a psychiatrist during that time because she was irritable and anxious. She acknowledged occasional brief panic outburst while separated from her husband who worked away from home frequently. She was also concerned that her baby would somehow know that she had thought about interrupting her pregnancy on account of feeling too sick. She felt inadequate for her older child because of her irritability and impatience. The psychiatrist diagnosed an anxiety disorder not otherwise specified (DSM-IV: 300.00) with fears about the upcoming delivery and prescribed citalopram 10 mg daily, which she took for two months. There was no other significant psychiatric history. The delivery was uneventful and the patient reported a slight “baby blues” of short duration. She managed well her immediate postpartum and cared for her newborn, but remained slightly dysphoric and anxious until her actual health problem. A week prior to the coronary dissection she was diagnosed with osteosclerosis and loss of audition that she attributed to abnormal hormonal levels during pregnancy. When first seen by our inpatient consultation Liaison team, she felt guilty of being unable to take care for her family and of causing them sorrow and suffering due to her current condition. Her sleep was disturbed by recurrent flashbacks of the events preceding...